About: Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$0.01 (+25.00%)
RAD ASX Radiopharm Theranostics Ltd
Radiopharm Theranostics Ltd share price
Atividade de preço de RAD
Último preço
$ 0,010
Variação (24h)
0,00 AUD (25,00%)
Volume
66.27K
Volume (média 4 sem.)
-
Abertura
$ 0,00
Variação do dia
$ 0,00 - $ 0,01
Fechamento anterior
$ 0,00
Último negócio
30 Oct, 5:10 am GMT+0
Atrasado
30 Oct, 5:10 am GMT+0
RAD price performance
Atrasado
30 Oct, 5:10 am GMT+0
quote.marketSignals